18:30 , Jan 11, 2019 |  BC Week In Review  |  Company News

Former Insys CEO pleads guilty to opioid prescription kickbacks

Michael Babich, former president and CEO of Insys Therapeutics Inc. (NASDAQ:INSY), pleaded guilty on Jan. 9 in conspiring to bribe physicians to unnecessarily prescribe Subsys fentanyl sublingual spray and defraud insurance companies. The opioid is...
18:32 , Aug 10, 2018 |  BC Week In Review  |  Company News

FDA reviewers say data are lacking on TIRF drug use

FDA reviewers pointed to significant data gaps for evaluating the REMS program for transmucosal immediate-release fentanyl (TIRF) drugs at a joint advisory committee meeting Aug. 3. Participants gave "important feedback" that insufficient data exists to...
21:33 , May 11, 2018 |  BioCentury  |  Finance

Seroquel stepping stone

The $538 million acquisition by Luye Pharma Group Ltd. (HKSE:2186) of Seroquel quetiapine fumarate from AstraZeneca plc (LSE:AZN; NYSE:AZN) will lay the commercial groundwork in new emerging markets for the Chinese pharma’s internal CNS pipeline....
21:18 , Apr 4, 2018 |  BC Extra  |  Politics & Policy

NIH, FDA announce opioids plans

At the National Rx Drug Abuse and Heroin Summit on Wednesday, NIH released details on its plans for spending $1.1 billion in FY18 to address the opioid abuse epidemic and FDA described plans for extending...
21:55 , Dec 1, 2017 |  BC Week In Review  |  Company News

Melinta acquires Medicines Co.'s infectious disease unit

Melinta Therapeutics Inc. (NASDAQ:MLNT) will acquire the infectious disease business unit of The Medicines Co. (NASDAQ:MDCO), including marketed drugs Vabomere meropenem/vaborbactam, Orbactiv oritavancin and Minocin IV minocycline. Medicines Co. will receive $270 million up front,...
00:16 , Nov 30, 2017 |  BC Extra  |  Company News

Melinta acquires Medicines Co.'s infectious disease unit

Melinta Therapeutics Inc. (NASDAQ:MLNT) will acquire the infectious disease business unit of The Medicines Co. (NASDAQ:MDCO), including marketed drugs Vabomere meropenem/vaborbactam, Orbactiv oritavancin and Minocin IV minocycline. Medicines Co. will receive $270 million up front,...
21:36 , Nov 2, 2017 |  BioCentury  |  Finance

Frazier follows performance

Frazier Healthcare Partners plans to ramp up company creation with its new $419 million life sciences fund. According to Frazier’s Jamie Topper, Frazier Life Sciences IX, which closed on Oct. 31, will invest $5-$30 million...
21:40 , Oct 27, 2017 |  BC Week In Review  |  Company News

Medicines Co. to cut workforce, focus on inclisiran

In its 3Q17 earnings announcement, The Medicines Co. (NASDAQ:MDCO) said it would reduce headcount to fewer than 60 employees to focus on developing inclisiran (PCSK9si). On Oct. 25, the company said it plans to start...
22:24 , Oct 25, 2017 |  BC Extra  |  Company News

Medicines Co. to cut workforce, focus on inclisiran

In its 3Q17 earnings announcement, The Medicines Co. (NASDAQ:MDCO) said it would reduce headcount to fewer than 60 employees to focus on developing inclisiran ( PCSK9si ). Next week, the company plans to start a...
07:16 , Jul 29, 2017 |  BioCentury  |  Finance

Show us your shorts

Absent any data showing a sustained impact of manipulative short selling on biotech valuations or their ability to raise capital, it is difficult to discern what direct benefit biotech companies would gain from BIO ’s...